Grufity logoGrufity logo

HAE

86.14USD+1.26(+1.48%)Market Closed

Haemonetics Corp

Market Summary

USD86.14+1.26Market Closed
1.48%

HAE Alerts

HAE Stock Price

RSI Chart

Valuation

Market Cap

4.3B

Price/Earnings

63.27

Price/Sales

4.17

Price/Cashflow

19.84

MarketCap/EBT

46.5

Price/Sales

Profitability

EBT Margin

8.98%

Return on Equity

8.79%

Return on Assets

3.72%

Fundamentals

Revenue

Revenue (TTM)

1.1B

Revenue Y/Y

24.01%

Revenue Q/Q

13.78%

Earnings

Earnings (TTM)

86.0M

Earnings Y/Y

123.46%

Earnings Q/Q

67.01%

Price Action

52 Week Range

43.5086.58
(Low)(High)

Last 7 days

3.1%

Last 30 days

6.8%

Last 90 days

16.8%

Trailing 12 Months

60.6%

Financial Health

Current Ratio

3.81

Investor Care

Buy Backs (1Y)

0.97%

Diluted EPS (TTM)

1.66

Peers (Alternatives to Haemonetics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-11.88% 44.84%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
14.69% -0.88%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
15.30% -16.82%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
10.69% 8.01%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
11.14% 17.68%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
8.87% -30.30%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
15.24% 17.79%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
33.98% -14.84%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-8.48% 5.83%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-16.73% -66.49%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
26.44% 24.39%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
9.49% -7.06%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
17.05% -10.97%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-6.64% -29.40%
-16.43
2.57
-8.79% -175.19%

Financials for Haemonetics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue5.6%1,0841,026993953934
Gross Profit6.5%575540506451433
Operating Expenses3.1%443430425411388
  S&GA Expenses4.9%357341340330323
  R&D Expenses0.1%4545474442
Earnings Before Taxes22.9%11392642127
Net Income27.1%8668432331
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets2.4%1,8651,8211,8601,8311,801
  Current Assets4.1%716688756729699
    Cash Equivalents12.2%241215259237192
  Inventory-8.4%255278293306323
  Net PPE6.8%308288258239224
  Goodwill-0.2%465466467468469
  Current Liabilities45.3%262180442355288
    LT Debt, Current749.2%58721414483
    LT Debt, Non Current-0.5%760763559633698
Shareholder's Equity-5.4%729770749731699
  Retained Earnings-8.1%204222202193169
  Additional Paid-In Capital-2.8%564580572567558
Shares Outstanding-1.4%5151515151
Float-3,658----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations20.2%260216172106110
  Share Based Compensation-1.1%2323242626
Cashflow From Investing-8.2%-139.26-128.71-86.34-480.93-475.05
Cashflow From Financing-59.6%-59.88-37.51-15.75426278
  Buy Backs-0
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on HAE?

74.2%


Probability that Haemonetics stock will be more than 20% underwater in next one year

53.1%


Probability that Haemonetics stock will be more than 30% underwater in next one year.

28.1%


Probability that Haemonetics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HAE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Haemonetics was unfortunately bought at previous high price.

Returns

Cumulative Returns on HAE

7.7%


10-Year Cumulative Returns

15.1%


7-Year Cumulative Returns

8.4%


5-Year Cumulative Returns

-10.0%


3-Year Cumulative Returns

What are the long-term rolling returns for HAE?

FIve years rolling returns for Haemonetics.

Which funds bought or sold HAE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Aurora Investment Counsel
REDUCED
-64.97
-2,410,000
1,633,000
1.24%
2022-11-23
Toroso Investments, LLC
REDUCED
-17.83
-28,000
395,000
0.02%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-1.84
5,437
48,000
0.03%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
3,098,000
3,098,000
0.04%
2022-11-21
FourThought Financial, LLC
UNCHANGED
-
9,000
82,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.94
485,000
4,751,000
0.01%
2022-11-16
Retirement Systems of Alabama
REDUCED
-0.08
1,607,000
13,517,000
0.06%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-147,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
65,000
544,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying HAE calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own HAE

Haemonetics News

MarketBeat

Haemonetics Co. (NYSE:HAE) Short Interest Update.2 days ago

Investor's Business Daily

HAE Fair Value

Recent SEC filings of Haemonetics

View All Filings
Date Filed Form Type Document
Nov 15, 2022
4
Insider Trading
Nov 08, 2022
10-Q
Quarterly Report
Nov 07, 2022
8-K
Current Report
Nov 03, 2022
4
Insider Trading
Oct 26, 2022
4
Insider Trading
Oct 26, 2022
4
Insider Trading
Oct 19, 2022
3
Insider Trading
Oct 19, 2022
8-K
Current Report
Oct 17, 2022
3
Insider Trading
Oct 11, 2022
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for HAE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-11
Simon, Christopher
GIFTED
-
-
-8,600
President & CEO
2022-11-01
Galvin Roy
ACQUIRED
-
-
2,382
President, Global Plasma & BC
2022-10-24
Strong Stewart W
SOLD
-6,029.25
80.39
-75
President, Global Hospital
2022-10-24
Basil Michelle L
SOLD
-14,470.2
80.39
-180
EVP and General Counsel
2022-09-19
Miller Laurie A.
SOLD
-16,165
76.25
-212
SVP, Human Resources
2022-09-19
Basil Michelle L
SOLD
-897,065
78.36
-11,448
EVP and General Counsel
2022-09-19
Basil Michelle L
ACQUIRED
365,743
42.0975
8,688
EVP and General Counsel
2022-09-15
Basil Michelle L
ACQUIRED
1,200,720
42.0451
28,558
EVP and General Counsel
2022-09-15
Basil Michelle L
SOLD
-2,632,590
77.892
-33,798
EVP and General Counsel
2022-09-06
Llorens Josep
SOLD
-7,451.78
73.78
-101
EVP, Global Manufacturing

1–10 of 50

Christopher A. Simon
2710
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE Income Statement

2022-10-01
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Oct. 01, 2022
Oct. 02, 2021
Oct. 01, 2022
Oct. 02, 2021
Income Statement [Abstract]    
Net revenues$ 297,485$ 239,897$ 558,943$ 468,425
Cost of goods sold139,607117,356258,802237,799
Gross profit157,878122,541300,141230,626
Operating expenses:    
Research and development10,89610,85321,79823,554
Selling, general and administrative92,41175,778184,638166,996
Amortization of Intangible Assets8,22111,40016,58823,779
Gain on closing of transaction38203829,603
Total operating expenses111,14698,031222,642204,726
Operating income46,73224,51077,49925,900
Interest and other expense, net(5,673)(4,588)(10,946)(8,986)
Income before provision for income taxes41,05919,92266,55316,914
Provision for income taxes7,8625,06613,4796,512
Net income$ 33,197$ 14,856$ 53,074$ 10,402
Basic income (loss) per share (in dollars per share)$ 0.65$ 0.29$ 1.04$ 0.20
Diluted income (loss) per share (in dollars per share)$ 0.64$ 0.29$ 1.03$ 0.20
Weighted average shares outstanding    
Basic (in shares)50,95351,03951,08950,989
Diluted (in shares)51,55851,45851,62051,358
Comprehensive income$ 25,659$ 14,420$ 38,773$ 10,413

HAE Balance Sheet

2022-10-01
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Oct. 01, 2022
Apr. 02, 2022
Current assets:  
Cash and cash equivalents$ 241,200$ 259,496
Accounts receivable, less allowance for credit losses of $2,495 at October 1, 2022 and $2,475 at April 2, 2022171,532159,376
Inventories, net254,680293,027
Prepaid expenses and other current assets48,37744,132
Total current assets715,789756,031
Property, plant and equipment, net307,844258,482
Intangible assets, less accumulated amortization of $395,822 at October 1, 2022 and $376,552 at April 2, 2022292,595310,261
Goodwill464,987467,287
Deferred tax asset4,2824,468
Other long-term assets79,61563,205
Total assets1,865,1121,859,734
Current liabilities:  
Notes payable and current maturities of long-term debt58,194214,148
Accounts payable61,48458,371
Accrued payroll and related costs44,59648,540
Other current liabilities97,901121,207
Total current liabilities262,175442,266
Long-term debt, net of current maturities759,552559,441
Deferred tax liability35,97428,727
Other long-term liabilities78,40279,876
Total stockholders’ equity  
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,605,499 shares at October 1, 2022 and 51,124,240 shares at April 2, 2022506511
Additional paid-in capital564,394572,476
Retained earnings204,364202,391
Accumulated other comprehensive loss(40,255)(25,954)
Total stockholders’ equity729,009749,424
Total liabilities and stockholders’ equity$ 1,865,112$ 1,859,734